Suzhou Fushilai Pharmaceutical Stock Current Valuation
| 301258 Stock | 27.94 0.05 0.18% |
Valuation analysis of Suzhou Fushilai Phar helps investors to measure Suzhou Fushilai's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Suzhou Fushilai's Free Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Other Non Cash Items is expected to grow to about 271.9 K, whereas Cash is forecasted to decline to about 271.6 M. Fundamental drivers impacting Suzhou Fushilai's valuation include:
Price Book 1.353 | Enterprise Value 1.2 B | Enterprise Value Ebitda 59.016 | Price Sales 6.308 | Trailing PE 142.15 |
Overvalued
Today
Please note that Suzhou Fushilai's price fluctuation is not too volatile at this time. Calculation of the real value of Suzhou Fushilai Phar is based on 3 months time horizon. Increasing Suzhou Fushilai's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Suzhou Fushilai is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Suzhou Stock. However, Suzhou Fushilai's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 27.94 | Real 22.04 | Hype 27.94 | Naive 27.64 |
The real value of Suzhou Stock, also known as its intrinsic value, is the underlying worth of Suzhou Fushilai Phar Company, which is reflected in its stock price. It is based on Suzhou Fushilai's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Suzhou Fushilai's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Suzhou Fushilai Pharmaceutical helps investors to forecast how Suzhou stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Suzhou Fushilai more accurately as focusing exclusively on Suzhou Fushilai's fundamentals will not take into account other important factors: Suzhou Fushilai Pharmaceutical Company Current Valuation Analysis
Suzhou Fushilai's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Suzhou Fushilai Current Valuation | 1.18 B |
Most of Suzhou Fushilai's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Suzhou Fushilai Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Suzhou Fushilai Pharmaceutical has a Current Valuation of 1.18 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is notably lower than that of the firm.
Suzhou Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Suzhou Fushilai's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Suzhou Fushilai could also be used in its relative valuation, which is a method of valuing Suzhou Fushilai by comparing valuation metrics of similar companies.Suzhou Fushilai is currently under evaluation in current valuation category among its peers.
Suzhou Fundamentals
| Return On Equity | 0.0099 | ||||
| Return On Asset | -0.0028 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 1.18 B | ||||
| Shares Outstanding | 91.67 M | ||||
| Shares Owned By Insiders | 66.71 % | ||||
| Shares Owned By Institutions | 1.07 % | ||||
| Price To Book | 1.35 X | ||||
| Price To Sales | 6.31 X | ||||
| Revenue | 489.29 M | ||||
| Gross Profit | 253.31 M | ||||
| EBITDA | 49 M | ||||
| Net Income | 112.18 M | ||||
| Total Debt | 170.45 M | ||||
| Book Value Per Share | 20.77 X | ||||
| Cash Flow From Operations | 94.77 M | ||||
| Earnings Per Share | 0.20 X | ||||
| Number Of Employees | 544 | ||||
| Beta | 0.53 | ||||
| Market Capitalization | 2.61 B | ||||
| Total Asset | 2.12 B | ||||
| Retained Earnings | 663.54 M | ||||
| Working Capital | 1.54 B | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 2.12 B | ||||
| Last Dividend Paid | 0.6 |
About Suzhou Fushilai Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Suzhou Fushilai Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Suzhou Fushilai using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Suzhou Fushilai Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Suzhou Stock
Suzhou Fushilai financial ratios help investors to determine whether Suzhou Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Suzhou with respect to the benefits of owning Suzhou Fushilai security.